Notification: Reference #jktl-nfat-cd16-av can only be ordered together with reference #jktl-nfat-cd16.
Reference #jktl-nfat-cd16lo-av can only be ordered together with reference #jktl-nfat-cd16lo.

ADCC reporter Jurkat T cell lines expressing high-affinity or low-affinity CD16

ADCC signaling pathway in Jurkat-Lucia™ NFAT-CD16 Cells

InvivoGen also offers:

• Clinically relevant biosimilar mAbs

• Raji-target cells (CTLA-4, PD-1, ICOS..)

Jurkat-Lucia™ NFAT-CD16 cells and Jurkat-Lucia™ NFAT-CD16-Low cells were engineered from the human T lymphocyte Jurkat cell line to assess the potency of specific antibodies/immunoglobulin for antibody-dependent cellular cytotoxicity (ADCC):

— Jurkat-Lucia™ NFAT-CD16 cells featuring the high-affinity CD16 allotype (V158)

— Jurkat-Lucia™ NFAT-CD16-Low cells featuring the low-affinity CD16 allotype (F158)

ADC C is one major mode of action of therapeutic monoclonal Abs (mAbs), whereas the cytotoxic outcome depends on the preferential IgG affinity of each Fc-gamma receptor (FcγR).

More details

Description:

Jurkat-Lucia™ NFAT-CD16 cells and Jurkat-Lucia™ NFAT-CD16-Low cells were generated from the Jurkat-Lucia™ NFAT cell line featuring an NFAT-inducible Lucia luciferase reporter gene. They stably express the high-affinity or low-affinity cluster of differentiation 16 (CD16), an FcγR binding the constant region of immunoglobulin G (IgG) [1]. CD16-mediated NFAT activation is readily assessable in the supernatant using QUANTI-Luc™ 4 Lucia/Gaussia, a detection reagent. Of note, Jurkat cells naturally express a functional NFAT (nuclear factor of activated T cells) transcription factor, which is involved in the early signaling events of ADCC and ADCP [2-3].

The induction of ADCC, reflected by the strong NFAT-mediated Lucia activation, was assessed when Jurkat-Lucia™ NFAT-CD16 or Jurkat-Lucia™ NFAT-CD16-Low (effector) cells were incubated with Raji (target) cells and an anti-hCD20 rituximab antibody (see figures).

Key features:

Endogenous NFAT expression
Stable CD16A (FcgRIIIA; V158 or F158 allotype) expression
Readily assessable Lucia luciferase reporter activity for NFAT activation

Applications:

Screening for novel Anti-CD16 monoclonal antibodies (mAbs)
Screening of engineered mAbs potency for ADCC

Learn more about Immune Checkpoint Antibodies

Read our review on Immune Checkpoint Blockade

References:

1. Nagelkerke S.Q. et al., 2019. Genetic variation in low-to-medium-affinity Fcγ receptors: functional consequences, disease associations, and opportunities for personalized medicine. Front. Immunol. 10:2237.
2. Shaw J-P. et al., 1998. Identification of a putative regulator of early T cell activation genes. Science. 241:202.
3. Leibson P.J., 1997. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity. 6:655.

Clear allRefined by

Products3

3 Search results: jktl-nfat-cd16